ICAP Considerations for the Introduction of TLD in National Programs


This document is intended to support country programs to develop clinical guidance and implementation plans for the introduction of the fixed-dose combination (FDC) tablet of tenofovir

(TDF), lamivudine (3TC) and dolutegravir (DTG), (TLD). The primary audiences for this document are

HIV program managers, technical working group members, national HIV guideline committees and other stakeholders contributing to the development of national normative guidance for HIV treatment and planning for the rollout of TLD.



6 views